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NGSDirect-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepatitis C virus (HCV)
infection. However, protease inhibitor (PI)-resistant viral variants have been often described. This study aimed
to examine HCV-NS3 protease variants at baseline and at 4 weeks under triple therapy. To this end, we analyzed
the presence of variants in HCV-NS3 protease region from peripheral blood samples of 16 patients infected with
HCV-1 at baseline and at 4 weeks of combined therapy with telaprevir, pegylated interferon, and ribavirin, using
next-generation sequencing. Several variants with synonymous and non-synonymous amino acid substitutions
were detected at both time points. Variants detected at low frequency corresponded to 74% (HCV-1a) and 35%
(HCV-1b) of non-synonymous substitutions. We found nine PI-resistance-associated variants (V36A, T54S,
V55I, Q80K, Q80R, V107I, I132V, D168E, M175L) in HCV-NS3 of 10 patients. There was no correspondence of
resistance-associated variant proﬁle between baseline and at 4 weeks. Moreover, these resistance variants at
baseline and short-term treatment are not good predictors of outcome under triple therapy. Our study also shows
a large number of others minor andmajor non-synonymous variants in HCV-NS3 early in telaprevir-based therapy
that can be important for further drug resistance association studies with newly developed PI agents.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis C virus (HCV) infection, aworldwide public health problem,
affects 135million people, i.e., 3% of theworld population [1]. Nearly 80%
of infected individuals develop chronic disease, often associated with
liver cirrhosis and hepatocellular carcinoma [1]. No vaccine has been
developed yet for HCV. Conventional therapy with pegylated interferon
(PEG-IFN) and ribavirin (RBV) is effective for only 40%of patients infected
with themost prevalent genotype (HCV-1) [2,3]. Therefore, direct-acting
antiviral (DAAs) agents, particularly protease inhibitors (PI), have
emerged as a major advance in hepatitis management, with several
DAAs currently under development [4].de Janeiro, Instituto de Biofísica
omolecular Firmino Torres de
Ilha do Fundão, Rio de Janeiro,
1 22808193.
. This is an open access article underEarly emergence of viral resistance mutations has been, however,
associated with PI monotherapy [5–8], with several of these mutations
showing cross-resistance to multiple PI agents [9]. Still, PI resistance
mutations are widespread and even present in naïve patients [10–15],
indicating thatmonotherapywith PImay select for resistancemutations
already present at baseline of treatment [6,16]. Consequently, previous
studies have suggested that the presence of resistancemutations before
treatment could be a reliable predictor of PI-based HCV therapy efﬁcacy
[12,17].
Even though routine baseline resistancemutation detection before PI
therapy is still prescribed as a prognostic tool [18], the predictive value of
thesemutations at baseline remains controversial. In fact, recent research
[19,20] has suggested that resistant variants that emerge during PI
therapymight not be the same as those identiﬁed at baseline. Moreover,
the presence of resistance mutations before treatment could not be
associated with therapy outcome in samples of non-cirrhotic patients
[7,21]. However, it is not yet possible to discriminate the inﬂuence of
potentially confounding factors on these results, including previousthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Proﬁle of hepatitis C virus-infected patients at commencement of telaprevir, pegylated
interferon, and ribavirin triple therapy.
No. of patients (men/women) 16 (8/8)
Age (years) 48.8 ± 13.4
Body weight (kg) 81.4 ± 13.5
Body mass index (kg/m2) 30.4 ± 6.8
Hemoglobin (g/dL) 14.8 ± 1.6
Platelet count (×104/μL) 17.6 ± 6.5
Alanine aminotransferase (IU/L) 107.2 ± 53.8
HCV genotype (1a/1b) 8/8
HCV RNA level (IU/mL) [median (range)] 962,112 (9,106–13,629,444)
Previous response (naïve/null/relapse) 10/3/3
Liver ﬁbrosis (F1–F2/F3–F4) 2/14
Cirrhosis (%) 31.3
147L. Hoffmann et al. / BBA Clinical 3 (2015) 146–151treatment, host-dependent factors, HCV-genotype, and the speciﬁc
antiviral agent used [21,22]. Also, it is not known whether these obser-
vations can be generalized to other populations of varying disease
severity.
1.1. Objectives
Our study investigates and compares variants of HCV-NS3
protease—an enzyme with a key role in viral replication—in chronic
PI-naïve patients infected with HCV genotype 1 (HCV-1) under triple
therapy (telaprevir, PEG-IFN, and RBV) at baseline and after 4 weeks of
treatment. To this end, we use high throughput sequencing technology
to detect even low-frequency resistance mutations, which can be
underestimated by conventional sequencing methodology.
2. Materials and methods
2.1. Study population
Sixteen patients infected with hepatitis C virus genotype 1 were
recruited from August to December, 2013 at the Hepatology Service of
the Hospital Universitário Clementino Fraga Filho (HUCCF), Rio de
Janeiro (RJ), Brazil. Patients who were chronically monoinfected with
HCV genotypes 1a or 1b were previously selected by their attendant
clinician to enroll in a telaprevir-based triple therapy protocol
(telaprevir (TVR) 750 mg, 3×/d + PEG-IFNα 1.5 μg/kg of body weightTable 2
Treatment outcome and number of synonymous and non-synonymous variants in NS3 HCV re
therapy.
HCV type Case Response to previous treatment Number of RAVs
PRE Week 4
1a 4 Naïve 2 ⁎
5 Naïve 0 ⁎
6 NULL 2 ⁎
7 Naïve 1 ⁎
8 Naïve 0 ⁎
12 Naïve 0 1
13 Naïve 0 ⁎
22 NULL 0 2
1b 3 REL 1 3
9 Naïve 0 0
10 REL 0 ⁎
11 NULL 0 ⁎
14 Naïve 1 ⁎
17 REL 0 4
19 Naïve 1 ⁎
20 Naïve 1 0
RAVs: resistance-associated variants; SVR: sustained viral response; REL: relapse; NR: non-re
incomplete 6 months follow-up).
⁎ Undetected viral load.
§ Deceased before end of treatment.once a week + RBV 1,000–1,500 mg/d, for 48 weeks). Triple therapy
is recommended for monoinfection with HCV-1, advanced liver ﬁbrosis
or cirrhosis, compensated liver disease, and absence of previous protease
inhibitor (PI) treatment. Written informed consent was obtained from
every patient.
2.2. HCV RNA isolation, NS3 protease region ampliﬁcation, and viral load
determination
Serum from 16 patients was collected at baseline (PRE) and after
4weeks (Week 4) of TVR/PEG-IFN/RBV treatment. HCVRNAwas isolated,
its NS3 protease region ampliﬁed and directly sequenced for HCV-
genotype conﬁrmation as previously described [15]. HCV genotypes
were obtained by comparing their sequences with those at NCBI
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and Los Alamos HCV databases
(http://hcv.lanl.gov/content/index).
HCV RNA levels were determined by real time PCR, using Abbott
RealTime HCV assay (Abbott GmbH,Wiesbaden, Germany) (quantiﬁca-
tion range of 12 to 100 million IU/mL) [23].
2.3. Next-generation sequencing (NGS) and HCV-NS3 protease region
analysis
High throughput sequencing was performed using Ion Torrent
Personal Genome Machine (PGM)™ sequencer (Life Technologies,
Carlsbad, CA). Ion Torrent adapter- and barcoded-ligated library was
prepared using NS3 protease PCR products (555 bp), according to Ion
protocol for long amplicon (N400 bp) library preparation and using
IonXpress™ Plus Fragment Library kit. Brieﬂy, PCRproductswere quan-
tiﬁed by Qubit® ﬂuorometer (Invitrogen), using Qubit® dsDNA BR
Assay kit, and enzymatically fragmented for 4 min, using Ion Shear™
Reagents. Fragments were then puriﬁed using Agencourt® AMPure®
XP Reagent. Fragmentation pattern was analyzed by semi-ﬂuidic elec-
trophoresis (Agilent® Bioanalyzer®, GE), using Agilent High Sensitivity
DNA Kit. Barcoded adapters were ligated, and fragments were size-
selected using E-gel® SizeSelect™ Agarose Gel. Emulsion PCR was
performed using Ion OneTouch™ and Ion OneTouch™ 200 Template
Kit. Ion sphere particle (ISP) enrichment was obtained using Ion
OneTouch™ ES and Ion OneTouch™ 200 Template Kit. Templated ISPs
were loaded onto 316™ or 318™ Chips and sequenced according to
Ion PGM™ 200 sequencing kit protocol.gion in patients infected with HCV at baseline (PRE) and after 4 weeks treatment of triple
Number of other
non-synonymous
variants
Number of
synonymous
variants
Outcome (triple therapy)
PRE Week 4 PRE Week 4
7 ⁎ 47 ⁎ SVR
6 ⁎ 44 ⁎ SVR
4 ⁎ 52 ⁎ REL
5 ⁎ 88 ⁎ REL
11 ⁎ 84 ⁎ §
5 5 48 28 SVR
4 ⁎ 30 ⁎ R
3 8 51 33 R
8 17 59 47 SVR
7 10 62 38 R
3 ⁎ 49 ⁎ R
3 ⁎ 45 ⁎ NR
4 ⁎ 53 ⁎ R
2 20 47 59 R
⁎ ⁎ 67 ⁎ R
9 6 47 54 NR
sponder; R: responder (undetected HCV RNA level after 48 weeks of treatment, but still
148 L. Hoffmann et al. / BBA Clinical 3 (2015) 146–151Sequences were analyzed with CLC Genomics Workbench v.7.5
software (CLC bio, Aarhus, Denmark) (http://www.clcbio.com). The
CLC resequencing tool was used to compare generated sequences
to HCV-1a (accession number AF009606) and HCV-1b (accession
number D90208) references. Reads were size- (b30 or N250 bp)
and quality-trimmed, and quality score N0.05 with maximum of 2
ambiguities was used. Synonymous and non-synonymous variants,
with frequency lower than 1%, were discarded.3. Results
We studied 16 patients infected with HCV genotypes 1a and 1b,
naïve for protease inhibitor-based therapy. All patients, chronically
infected, were selected by the Hepatology Department for triple therapy.
Most of them had severe liver ﬁbrosis at the beginning of treatment.
Table 1 shows the demographic, clinical, and virological characterization
of the population. Six patients had received previous therapy withTable 3
Treatment outcome, HCV RNA level, and frequencies (f) of non-synonymous variants in NS3 H
(W4) treatment of triple therapy.
Case 4 Case 5 Case 6
Outcome SVR SVR REL
PRE-W4 PRE-W4 PRE-W4
HCV RNA
(log IU/mL)
5.5–⁎ 6.29–⁎ 5.58–⁎
Non-synonymous variants (f %)
A1E
P2L 4.7–⁎
I3F
I3L 3.2–⁎
T4R 1.1–⁎
T4K 1.4–⁎
A5P
A5L
Y6H 5.1–⁎ 2.6–⁎
A7S
L13F
I18V 89.5–⁎
G23S
Q28E
V33I
V36A 3.2–⁎
T40A
A45T
I48V
T54S 2.8–⁎
V55I 2.7–⁎
T61S
R62K
I64V
S66T 2.5–⁎
P67S
P70L
Q80K 3.3–⁎
S91A
V107I
R109G 1.2–⁎
V113I
R130Q 2.3–⁎
A147S 5.6–⁎
L153I 98.2–⁎ 92.6–⁎ 99.0–⁎
L153V
A157V 9.4–⁎
N174H 11.3–⁎
N174S 13.7–⁎
M179L
R180S
S181P
In bold: variants associated with resistance to protease inhibitors (underlined bold: variants as
§ Deceased before the end of treatment.
⁎ Undetected viral load.PEG-IFN and RBV, showing null (n = 3) or relapsed response (n = 3)
(Tables 1 and 2).
After size- and quality trimming, an average of 182,093 reads (mean
size of 157 bp) of the NS3 protease gene region were obtained for each
sample. At 4 weeks of treatment, we obtained HCV-NS3 protease
variants from 6 of the 16 patients studied, while 10 had no detectable
HCV RNA. NGS sequencing was able to detect even low-frequency
(b20%) variants. Several synonymous and non-synonymous substitu-
tions were identiﬁed at baseline and 4 weeks of treatment (Table 2).
Four of the six patients with detectable HCV-RNA levels at 4 weeks
were infected with HCV-1b. In those patients, the total number of
variants (synonymous and non-synonymous) at 4 weeks was either
similar to or higher than at baseline. Triple therapy was discontinued
before 48 weeks in three patients, either because of HCV RNA level
above 1,000 IU/mL (considered non-responders, NR) or death (one
case). All others completed the 48 weeks of treatment. Telaprevir-based
therapy was effective in 11 cases: 4 patients showed sustained viral
response (SVR, undetected HCV RNA level at 6 months after therapy),CV region in patients infected with HCV genotype 1a at baseline (PRE) and after 4 weeks
Case 7 Case 8 Case 12 Case 13 Case 22
REL § SVR R R
PRE-W4 PRE-W4 PRE-W4 PRE-W4 PRE-W4
6.66–⁎ 7.13–⁎ NI–b1.08 5.57–⁎ 6.25–1.45
11.5–0.0
9.0–⁎ 3.2–⁎
3.4–⁎
2.7–0.0
5.3–0.0
12.3–⁎
9.0–⁎
3.8–⁎ 3.5–⁎ 1.6–0.0
2.7–⁎
5.7–⁎
1.0–⁎
98.8–⁎
97.4–⁎
95.0–0.0
2.0–⁎
63.8–⁎ 4.3–0.0
0.0–99.4 0.0–98.8
0.0–94.5
1.6–0.0
34.6–⁎
1.0–⁎
4.4–99.6 0.0–99.5
95.9–⁎
0.0–1.1
98.4–97.1
1.9–⁎
0.0–97.1
98.2–⁎ 0.0–99.4 98.9–⁎ ⁎–97.4
0.0–2.4
0.0–96.8 0.0–96.4
0.0–92.1
0.0–6.9 0.0–99.5
sociated with telaprevir resistance); NI: not informed.
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and are completing the 6 months follow-up to characterize SVR.
Triple therapy was not effective for 2 of 3 patients with null response
to previous PEG-IFN/RBV treatment, while the previously relapsed
ones showed either SVR or undetected HCV RNA level at 48 weeks
(Table 2).
Tables 3 and 4 show the frequency of variantswith non-synonymous
substitutions in HCV-NS3 protease region in sub-types 1a and 1b,
before and at 4 weeks of PI-based therapy. Low-frequency variants
corresponded to 74% and 35% of non-synonymous mutations identiﬁedTable 4
Treatment outcome, HCV RNA level, and frequencies (f) of non-synonymous variants in NS3 H
(W4) treatment of triple therapy.
Case 3 Case 9 Case 10
Outcome SVR R R
PRE-W4 PRE-W4 PRE-W4
HCV RNA
(log IU/mL)
5.10–1.08 5.79– b 1.08 6.20–⁎
Non-synonymous variants (f %)
S7A 0.0–25.6
I18V 0.0–1.4
D30E 97.1–0.0 94.4–94.2
L36V 99.3–0.0 99.2–99.2
T40A
S42T 98.1–⁎
S42F
F43L
T46A
V48A
V48I 99.0–96.0
N49S 99.1–0.0
T54S 0.0–100
V55I 0.0–97.6
Y56F 99.0–99.2 98.2–⁎
S61T 0.0–98.5
K62R 0.0–100
L64M 0.0–100
G66T 0.0–100
K68N 0.0–97.8
K68T
I71V 0.0–100
T72I 0.0–98.5
T72N
N77S 98.2–99.8
Q80R
W85R 0.0–1.1
P89Q
R92H
P96Q
M94I 1.8–0.0
M94L 99.7–88.7 0.0–98.8
V114I 0.0–96.1 0.0–96.6
G120V
D121E 0.0–11.0
P131S 1.5–0.0
I132V 99.7–0.0
L144F 0.0–1.2
S147A 0.0–96.7
S147L 85.5–0.0
S147P
V150A 0.0–99.5
V151A
D168E
I170V 99.9–0.0 98.8–99.9 99.3–⁎
I170M 98.5–0.0
V172I
S174A
S174N 0.0–97.8
M175L 0.0–97.8
M179L 0.0–98.6
S181P 0.0–99.6
In bold: variants associated with resistance to protease inhibitors (underlined bold: variants as
⁎ Undetected viral load.in HCV-1a and -1b, respectively. All patients, in both HCV genotypes,
presentedmore than oneHCV-NS3 protease non-synonymousmutation.
On the other hand, most of the detected variants were identiﬁed in only
one patient, while few (29% for HCV-1a and 42% for HCV-1b) showed
high prevalence. Only 4.8% (out of 42 substitutions for HCV-1a) and
13.5% (out of 52 substitutions for HCV-1b) of the variants present at
baseline remained at 4 weeks, showing no correspondence between
variant proﬁle mutations emerged under therapy and those at baseline.
In 10 out of 16 patients, we identiﬁed 9 non-synonymous substitu-
tions in the NS3 protease variants previously associated with proteaseCV region in patients infected with HCV genotype 1b at baseline (PRE) and after 4 weeks
Case 11 Case 14 Case 17 Case 19 Case 20
NR R R R NR
PRE-W4 PRE-W4 PRE-W4 PRE-W4 PRE-W4
5.98–⁎ 5.86–⁎ 6.21–NI 6.23–⁎ 3.96–1.08
46.2–0.0 40.8–0.0
93.5–⁎ 95.8–0.0
98.4–⁎
0.0–1.5
0.0–70.0
0.0–1.1
0.0–4.2
1.1–0.0
99.1–0.0
98.8–⁎ 0.0–92.9
0.0–94.7
0.0–94.7
99.3–⁎ 99.0–4.0
0.0–96.0
0.0–96.4
0.0–92.6
0.0–95.8
0.0–96.2
98.5–0.0
0.0–99.8 99.9–99.8
99.4–0.0
0.0–94.2
0.0–1.1
96.9–⁎
0.0–1.5
0.0–98.3
0.0–1.2
0.0–4.5
99.3–⁎ 0.0–1.2
0.0–97.6
0.0–1.0
0.0–98.8
99.6–⁎
33.7–⁎
98.1–97.7
1.2–⁎ 97.7–0.0
0.0–1.1
99.3–0.0
0.0–95.5
0.0–95.5
0.0–99.2
sociated with telaprevir resistance); NI: not informed.
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telaprevir (TVR), boceprevir (BOC), danoprevir (ITMN-191), paritaprevir
(ABT-450)], T54S [TVR, BOC, simeprevir (TMC-435), faldaprevir
(BI-201335)], V55I (BOC, ITMN-191, ABT-450), Q80K (TMC-435), Q80R
(TMC-435), V107I (BOC), I132V (TVR), D168E [TVR, BOC, TMC-435,
BI-201335, ITMN-191, asunaprevir (ASV)] and M175L (BOC) (Tables 3
and 4). Five of these patients presented more than one resistance muta-
tion, most of which confer cross-resistance to more than one drug. For
HCV-1a infected patients, resistance mutations had a low frequency
(b4%) at baseline yet high frequency (N94%) at 4 weeks. Conversely, the
frequency of most resistance mutations in HCV-1b infected patients was
high at both time points. It is noteworthy that, for both genotypes, virus
resistance mutations identiﬁed at baseline did not persist at 4 weeks,
whereas those detected at the latter time point were not present at base-
line. Patients with resistant mutations at baseline showed diverse
outcomes—from SVR to NR—suggesting no correlation between baseline
proﬁle and outcome. On the other hand, most patients presented also
non-synonymous substitutions not yet described as RAVs, both at base-
line and Week 4, which could potentially impact outcome (Table 3 and
4). The presence of high frequency telaprevir RAVs at baseline (cases 3,
14 and 19) did not predict therapy failure. Despite I132V variant high
prevalence at baseline, it was not detected at week 4, while T54S, not
detected at baseline, showed high frequency at week 4. Case 12, with
no RAVs at baseline, presented telaprevir RAV-T54S variant at week 4,
even though had SVR.4. Discussion
Byusing ultra-deep sequencing,we conducted a thorough assessment
of HCV-NS3 protease variants in chronic PI-naïve patients infected with
HCV-1a and HCV-1b under telaprevir-based triple therapy at base-
line and after 4 weeks of treatment. Several synonymous and non-
synonymous substitutions, including those at very low frequencies,
were detected for both genotypes at both time points. However,
there was no correspondence between resistance variants detected
at baseline and at 4 weeks. Our results showed that triple therapy
was effective for 11 patients (69%) since they showed SVR or had
undetected HCV RNA level at 48 weeks of treatment (ﬁnal sustained
response will be available at 6 months after the end of treatment).
The observation that resistancemutations at baselinewere not iden-
tiﬁed at 4 weeks is in contrast to previous suggestions that the wide-
spread natural occurrence of HCV-resistant variants could explain the
detection of resistance variants following PI monotherapy [16]. Non-
synonymous resistance variants were detected at baseline in the
peripheral blood of all patients, supporting the existence of circulating
viral populations. The improved detection capacity of the NGS method
used here may explain the observation of more highly prevalent and
variablemutations at baseline in the peripheral blood than those detect-
ed by previous studies in Brazil [11,15,24,25] and other countries [12,18,
26,27]. Our results therefore conﬁrm and expand previous research,
providing a comprehensive databank of non-synonymous HCV-NS3
variants induced by short-term therapy, which can be of potential
importance for future drug resistance association studies involving
approved and newly developed PI agents.
The predictive potential of baseline resistance variants remains
controversial. Some authors still support routine baseline resistance
mutation detection before PI therapy [18], while others report that
resistant variants emerging during PI therapy are the same as those
identiﬁed at baseline [19,20]. However, most studies have investigated
emerging resistance mutations late in treatment or post-treatment,
i.e., at the time of viral load re-elevation [19]. Although in our study
only six patients had detectable HCV RNA level under treatment,
resistance variants were detected already at 4 weeks, yielding early
virus-diversity information that could be important for understanding
viral-variant dynamics and guiding treatment.Recent studies showed no association between the presence of resis-
tancemutations before treatment and treatment outcome in samples of
non-cirrhotic patients [7,21]. Our data potentially support and expand
the previous observation to patients with severe liver ﬁbrosis and
cirrhosis since emerging resistance variants at 4 weeks were different
from those present at baseline (see also [28]). On the other hand, recent
study suggested that baseline variants proﬁle could be predictive of out-
come when accompanied by previous failure to classical PEG-IFN/RBV
treatment [22]. Moreover, since resistance variants identiﬁed early in
treatment were not concordant with baseline proﬁle, the predictive
prognostic power of those therapy-induced substitutions should be
replicate in other cohorts to further support our interpretation.
In conclusion, our ﬁndings support the concept that HCV-NS3
resistant variants at baseline are not reliable predictors of resistant
mutations that may emerge under PI treatment. Non-synonymous
HCV-NS3 variants induced by short-term therapy, instead, could be
important for future drug development as well as for better under-
standing viral-variant dynamics and guiding treatment. In addition,
our study showed a large number of non-synonymous substitutions
not yet described in HCV-NS3 protease region from patients both at
baseline and short-term telaprevir-based therapy that can be useful
for drug resistance association studies.
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